The letter by Claggett and Wei focuses on the statistical methods used to perform our meta-analysis of the cardiovascular (CV) safety of rosiglitazone.1 Specifically, these authors question the robustness of the P values and propose alternative statistical methods that yield higher P values. The purpose of any meta-analysis is not to perform every possible statistical approach to the data, but rather to characterize the pattern of outcomes associated with the studied treatment. We believe strongly that authors should prespecify the methods used and stick closely to the selected approach, which we did. The Peto and Mantel Haenszel methods are time-honored analytic approaches that have been used by many other authors. Regarding the robustness of the data, it must be understood that rosiglitazone has been marketed for 11 years. During that period, the drug maker carefully avoided performing any high-quality CV outcomes studies, thereby limiting the availability of CV safety data. Importantly, the majority of clinical trials used in our analysis were unpublished and available only because of a court settlement requiring the company to publicly disclose clinical trial findings. We were forced to use study-level data, not patient-level data, in our analyses. Accordingly, the most important limitations of our meta-analysis relate to the behavior of the drug maker in avoiding CV safety studies, not the statistical methods used to analyze the available clinical trials. The use of study-level data is a more serious limitation than the precise statistical methods used to calculate P values. Fortunately, the Food and Drug Administration (FDA) had access to patient-level data, enabling use of more robust time-to-event methods. The FDA analysis of patient-level data reported a hazard ratio (HR) for myocardial infarction of 1.80 (95% CI, 1.03-3.25).2 Sensitivity analyses using the end point of myocardial ischemia yielded a significant HR of 1.34 (95% CI, 1.07-1.70). Strikingly, the FDA reviewer also reanalyzed the RECORD trial, reporting an HR for myocardial infarction of 1.38 (95 CI, 0.99-1.93), which was very similar to our findings using the Peto odds ratio.2 Given the FDA findings, we believe that our reported odds ratios and P values accurately represent the hazards of rosiglitazone. In 2010, the FDA's July 14 Advisory Committee agreed, voting overwhelmingly that rosiglitazone increases the risk of ischemic CV events and recommending either withdrawal of the drug from the market or severe restrictions on its availability.
Thank you for submitting a comment on this article. It will be reviewed by JAMA Internal Medicine editors. You will be notified when your comment has been published. Comments should not exceed 500 words of text and 10 references.
Do not submit personal medical questions or information that could identify a specific patient, questions about a particular case, or general inquiries to an author. Only content that has not been published, posted, or submitted elsewhere should be submitted. By submitting this Comment, you and any coauthors transfer copyright to the journal if your Comment is posted.
* = Required Field
Disclosure of Any Conflicts of Interest*
Indicate all relevant conflicts of interest of each author below, including all relevant financial interests, activities, and relationships within the past 3 years including, but not limited to, employment, affiliation, grants or funding, consultancies, honoraria or payment, speakers’ bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued. If all authors have none, check "No potential conflicts or relevant financial interests" in the box below. Please also indicate any funding received in support of this work. The information will be posted with your response.
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Web of Science® Times Cited: 2
Customize your page view by dragging & repositioning the boxes below.
More Listings atJAMACareerCenter.com >
Enter your username and email address. We'll send you a link to reset your password.
Enter your username and email address. We'll send instructions on how to reset your password to the email address we have on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.